Details

Autor(en) / Beteiligte

• Challal, Salima
• Semerano, Luca
• Nunes, Hilario
• Valeyre, Dominique
• Boissier, Marie-Christophe
• Saidenberg-Kermanac’h, Nathalie

Titel

Teriparatide for osteoporosis in patients with sarcoidosis: Report on risk-benefit ratio in four cases

Ist Teil von

• Joint, bone, spine : revue du rhumatisme, 2016-05, Vol.83 (3), p.344-345

Ort / Verlag

France: Elsevier SAS

Erscheinungsjahr

2016

Quelle

Elsevier ScienceDirect Journals

Beschreibungen/Notizen

• Abstract Objectives For patients with sarcoidosis, no consensus exists about the management of osteoporosis, whether related or unrelated to glucocorticoid therapy. Methods We report the first series of 4 patients with histologically documented sarcoidosis who received teriparatide therapy for severe osteoporosis manifesting as a fracture cascade with multilevel vertebral fractures. When teriparatide was started, 1 patient was receiving 10 mg of prednisone equivalents per day, 1 was progressively tapering glucocorticoid dose, 2 had never received any glucocorticoid treatment. Results In all 4 patients, teriparatide was effective in halting the fracture cascade, including in the 2 patients who remained on long-term glucocorticoid therapy. None of the patients developed hypercalcemia. During teriparatide therapy, 3 patients underwent a flare or a complication of sarcoidosis. Only the patient on stable glucocorticoid treatment did not present any adverse event. Before teriparatide initiation, sarcoidosis had been well controlled in all 3 patients for several years. Conclusions Even if the implication of teriparatide is unclear, the appearance of adverse events in 3 out of 4 patients in this small series suggest caution in the use of teriparatide in patients with sarcoidosis.